{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:43:01Z","timestamp":1792896181361,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,11,23]],"date-time":"2017-11-23T00:00:00Z","timestamp":1511395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.jbo.2017.11.004","type":"journal-article","created":{"date-parts":[[2017,11,24]],"date-time":"2017-11-24T19:01:07Z","timestamp":1511550067000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries"],"prefix":"10.1016","volume":"11","author":[{"given":"Roger","family":"von Moos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Body","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Rider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"de Courcy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debajyoti","family":"Bhowmik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Gatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Hechmati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbo.2017.11.004_bib1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.critrevonc.2017.04.008","article-title":"Systematic review and meta-analysis on the proportion of patients with breast cancer who develop bone metastases","volume":"115","author":"Body","year":"2017","journal-title":"Crit. Rev. Oncol. Haematol."},{"issue":"Suppl. 4","key":"10.1016\/j.jbo.2017.11.004_bib2","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1634\/theoncologist.9-90004-14","article-title":"Bisphosphonates: clinical experience","volume":"9","author":"Coleman","year":"2004","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.jbo.2017.11.004_bib3","first-page":"15","article-title":"Pathophysiology of bone cancer pain","volume":"3","author":"Sabino","year":"2005","journal-title":"J. Support. Oncol."},{"issue":"2","key":"10.1016\/j.jbo.2017.11.004_bib4","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s10549-011-1475-5","article-title":"Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999\u20132007)","volume":"129","author":"Yong","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.jbo.2017.11.004_bib5","first-page":"1327","article-title":"Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases","volume":"24","author":"Von Moos","year":"2016","journal-title":"Support. Cancer Care"},{"issue":"5","key":"10.1016\/j.jbo.2017.11.004_bib6","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long-term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2017.11.004_bib7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1471-2407-11-29","article-title":"Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark","volume":"11","author":"Jensen","year":"2011","journal-title":"BMC Cancer"},{"issue":"8 Suppl.","key":"10.1016\/j.jbo.2017.11.004_bib8","doi-asserted-by":"crossref","first-page":"S1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2017.11.004_bib9","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/bjc.2013.6","article-title":"Breast Cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000\u20132007: a population-based study","volume":"108","author":"Walters","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jbo.2017.11.004_bib10","unstructured":"N. Howlader, A.M. Noone, M. Krapcho, SEER Cancer Statistics Review, 1975\u20132012. Table 4.13: Cancer of the female breast (invasive) 5-year relative and period survival by race, diagnosis, year, age and stage at diagnosis, 2015. \u3008http:\/\/seer.cancer.gov\/archive\/csr\/1975_2012\/browse_csr.php?SectionSEL=4&pageSEL=sect_04_table.13.html\u3009. (Accessed 2 November 2016)."},{"issue":"2","key":"10.1016\/j.jbo.2017.11.004_bib11","first-page":"7","article-title":"Importance of metastasis site in survival of patients with breast cancer","volume":"1","author":"Y\u00fccel","year":"2014","journal-title":"Austin J. Med. Oncol."},{"issue":"4","key":"10.1016\/j.jbo.2017.11.004_bib12","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3816\/SCT.2005.n.017","article-title":"Survival-adjusted multiple-event analysis for the evaluation of treatment effects of zoledronic acid in patients with bone metastases from solid tumours","volume":"2","author":"Major","year":"2005","journal-title":"Support. Cancer Ther."},{"issue":"5","key":"10.1016\/j.jbo.2017.11.004_bib13","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.jbo.2017.11.004_bib14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jbo.2014.04.001","article-title":"Health resource utilization associated with skeletal-related events in patients with bone metastases: results from a multinational retrospective \u2013 prospective observational study \u2013 a cohort from 4 European countries","volume":"3","author":"Hoefeler","year":"2014","journal-title":"J. Bone Oncol."},{"issue":"5","key":"10.1016\/j.jbo.2017.11.004_bib15","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3111\/13696998.2013.779921","article-title":"Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study","volume":"16","author":"Hechmati","year":"2013","journal-title":"J. Med. Econ."},{"issue":"6","key":"10.1016\/j.jbo.2017.11.004_bib16","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3111\/13696998.2016.1150852","article-title":"Cost of skeletal complications from bone metastases in six European countries","volume":"19","author":"Pereira","year":"2016","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.jbo.2017.11.004_bib17","unstructured":"Novartis Pharmaceuticals Corporation, Zometa (zoledronic acid): summary of product characteristics, (Accessed March 2016), 2009."},{"key":"10.1016\/j.jbo.2017.11.004_bib18","unstructured":"A.E. B.V, Xgeva (denosumab): Summary of Product Characteristics (Accessed March, 2016)."},{"issue":"12","key":"10.1016\/j.jbo.2017.11.004_bib19","first-page":"3497","article-title":"Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid","volume":"21","author":"von Moos","year":"2013","journal-title":"Support Care Cancer"},{"issue":"Suppl. 3","key":"10.1016\/j.jbo.2017.11.004_bib20","article-title":"Bone health in cancer patients: ESMO Clinical Practice Guidelines","volume":"25","author":"Coleman","year":"2014","journal-title":"Ann. Oncol."},{"issue":"16","key":"10.1016\/j.jbo.2017.11.004_bib21","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1200\/JCO.2011.39.2381","article-title":"Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer","volume":"30","author":"Fisch","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.jbo.2017.11.004_bib22","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/cncr.27789","article-title":"Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid","volume":"119","author":"Cleeland","year":"2013","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.jbo.2017.11.004_bib23","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1185\/03007990802457040","article-title":"Real-world physician and patient behaviour across countries: disease-specific Programmes - a means to understand","volume":"24","author":"Anderson","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"issue":"2","key":"10.1016\/j.jbo.2017.11.004_bib24","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0304-3959(94)00178-H","article-title":"When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function","volume":"61","author":"Serlin","year":"1995","journal-title":"Pain"},{"issue":"2","key":"10.1016\/j.jbo.2017.11.004_bib25","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/pme.12299","article-title":"Assessing analgesic use in patients with advanced cancer: development of a new scale--the Analgesic Quantification Algorithm","volume":"15","author":"Chung","year":"2014","journal-title":"Pain Med."},{"issue":"3","key":"10.1016\/j.jbo.2017.11.004_bib26","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol--a new facility for the measurement of health-related quality of life","volume":"16","author":"Group","year":"1990","journal-title":"Health Policy"},{"issue":"3","key":"10.1016\/j.jbo.2017.11.004_bib27","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1200\/JCO.1997.15.3.974","article-title":"Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument","volume":"15","author":"Brady","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2017.11.004_bib28","first-page":"335","article-title":"Prevalence of bone metastases and bone-targeting agent use among solid tumor patients in the United States","volume":"7","author":"Hernandez","year":"2015","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.jbo.2017.11.004_bib29","article-title":"The use of bisphosphonates in the management of bone involvement from solid tumours and haematological malignancies - a European survey","author":"Lebret","year":"2016","journal-title":"Eur. J. Cancer Care"},{"issue":"Suppl. 3","key":"10.1016\/j.jbo.2017.11.004_bib30","article-title":"Bone health in cancer patients: ESMO Clinical Practice Guidelines","volume":"25","author":"Coleman","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbo.2017.11.004_bib31","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.breast.2016.10.001","article-title":"3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3)","volume":"31","author":"Cardoso","year":"2017","journal-title":"Breast"},{"issue":"3","key":"10.1016\/j.jbo.2017.11.004_bib32","first-page":"209","article-title":"How accurate are physicians' clinical predictions of survival and the available prognostic tools in estimating survival times in terminally ill cancer patients? A systematic review","volume":"13","author":"Chow","year":"2001","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"issue":"3","key":"10.1016\/j.jbo.2017.11.004_bib33","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s10549-010-0981-1","article-title":"Prognostic factors for skeletal complications from metastatic bone disease in breast cancer","volume":"123","author":"Brown","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"issue":"22","key":"10.1016\/j.jbo.2017.11.004_bib34","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid","volume":"23","author":"Coleman","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jbo.2017.11.004_bib35","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cncr.23529","article-title":"Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid","volume":"113","author":"Lipton","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2017.11.004_bib36","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/1471-2407-9-272","article-title":"Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity","volume":"9","author":"Major","year":"2009","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.jbo.2017.11.004_bib37","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3928\/0147-7447-20010601-25","article-title":"Evaluation of the risk of pathologic fractures secondary to metastatic bone disease","volume":"24","author":"Patel","year":"2001","journal-title":"Orthopedics"},{"issue":"2","key":"10.1016\/j.jbo.2017.11.004_bib38","first-page":"197","article-title":"Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting","volume":"18","author":"Trinkaus","year":"2010","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.jbo.2017.11.004_bib39","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial","volume":"317","author":"Himelstein","year":"2017","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.jbo.2017.11.004_bib40","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(13)70174-8","article-title":"Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial","volume":"14","author":"Amadori","year":"2013","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.jbo.2017.11.004_bib41","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/cam4.403","article-title":"Prevalence of renal impairment and use of nephrotoxic agents among patients with bone metastases from solid tumors in the United States","volume":"4","author":"Arellano","year":"2015","journal-title":"Cancer Med."},{"issue":"5","key":"10.1016\/j.jbo.2017.11.004_bib42","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann. Oncol."},{"issue":"16","key":"10.1016\/j.jbo.2017.11.004_bib43","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.jbo.2017.11.004_bib44","first-page":"447","article-title":"Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer","volume":"24","author":"Stopeck","year":"2016","journal-title":"Support. Cancer Care"},{"issue":"Suppl. 6","key":"10.1016\/j.jbo.2017.11.004_bib45","article-title":"Management of cancer pain: esmo Clinical Practice Guidelines","volume":"22","author":"Ripamonti","year":"2011","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.jbo.2017.11.004_bib46","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10147-012-0414-8","article-title":"Treatment of bone metastases before the onset of pain","volume":"18","author":"Costa","year":"2013","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2017.11.004_bib47","article-title":"Evidence on the analgesic role of bisphosphonates and denosumab in the treatment of pain due to bone metastases: a systematic review within the European Association for Palliative Care guidelines project","author":"Porta-Sales","year":"2016","journal-title":"Palliat. Med."},{"issue":"1","key":"10.1016\/j.jbo.2017.11.004_bib48","first-page":"21","article-title":"Patients' preferences for bone metastases treatments in France, Germany and the United Kingdom","volume":"23","author":"Hechmati","year":"2015","journal-title":"Support. Care Cancer"},{"issue":"3","key":"10.1016\/j.jbo.2017.11.004_bib49","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat. Rev."},{"issue":"12","key":"10.1016\/j.jbo.2017.11.004_bib50","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1093\/annonc\/mdn419","article-title":"Prevalence of undertreatment in cancer pain. A review of published literature","volume":"19","author":"Deandrea","year":"2008","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.jbo.2017.11.004_bib51","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1038\/sj.bjc.6605053","article-title":"Pattern and quality of care of cancer pain management. Results from the Cancer Pain Outcome Research Study Group","volume":"100","author":"Apolone","year":"2009","journal-title":"Br. J. Cancer"},{"issue":"9","key":"10.1016\/j.jbo.2017.11.004_bib52","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1056\/NEJM199403033300902","article-title":"Pain and its treatment in outpatients with metastatic cancer","volume":"330","author":"Cleeland","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2017.11.004_bib53","unstructured":"N.C.C. Network, NCCN clinical practice guidelines in oncology. Adult cancer pain version. \u3008http:\/\/www.nccn.org\u3009. (Accessed 30 October 2016)."},{"issue":"2","key":"10.1016\/j.jbo.2017.11.004_bib54","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/S1470-2045(12)70040-2","article-title":"Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC","volume":"13","author":"Caraceni","year":"2012","journal-title":"Lancet Oncol."}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137417301367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137417301367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:16:30Z","timestamp":1761941790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137417301367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":54,"alternative-id":["S2212137417301367"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2017.11.004","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2017.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}]}}